Docoh
Loading...

MTP Midatech Pharma

Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in house programmes as well as partnered programmes. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is a innovative nanosaccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is a edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale ie i. chemotherapy - improved and targeted delivery of existing chemotherapeutic agents to tumor sites, as well as ii. immunotherapy - enhanced uptake of new immuno-moieties by immune cells that can then mount an immune attack against cancer cells. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

MTP stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

30 Apr 21
18 Sep 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

5.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 15 11 +36.4%
Opened positions 6 3 +100.0%
Closed positions 2 2
Increased positions 3 5 -40.0%
Reduced positions 5 1 +400.0%
13F shares
Current Prev Q Change
Total value 2.17M 2.12M +2.5%
Total shares 1.12M 1.1M +1.9%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Lombard Odier Asset Management 591K $1.06M +49.4%
Renaissance Technologies 210.49K $438K -40.0%
MS Morgan Stanley 142.51K $296K +54.1%
CS Credit Suisse 38.72K $81K NEW
SNEX StoneX 32.48K $68K -0.3%
Citadel Advisors 25.72K $54K -81.8%
Two Sigma Securities 22.37K $47K NEW
VIRT Virtu Financial 16.74K $35K -65.7%
Advisor 11K $23K +83.3%
Susquehanna International 10.69K $22K NEW
Largest transactions
Shares Bought/sold Change
Lombard Odier Asset Management 591K +195.5K +49.4%
Renaissance Technologies 210.49K -140.55K -40.0%
Citadel Advisors 25.72K -115.39K -81.8%
MS Morgan Stanley 142.51K +50.01K +54.1%
CS Credit Suisse 38.72K +38.72K NEW
VIRT Virtu Financial 16.74K -31.99K -65.7%
Two Sigma Securities 22.37K +22.37K NEW
UBS UBS Group AG - Registered Shares 7.71K -16.67K -68.4%
Susquehanna International 10.69K +10.69K NEW
BMO Bank of Montreal 10K +10K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: adaptable, affirmed, aforementioned, alive, anesthesiologist, apparent, appeal, appealing, apportionment, batch, BBA, behavior, Benchmark, Biden, bilateral, biometric, bioresorbable, biosimilar, breadth, cerebellum, cerebrospinal, cerebrum, circulate, constitutionality, cord, CSF, Easier, Easy, economy, EEA, entirety, envisage, envisaged, ePrivacy, fiduciary, filer, fluid, footprint, formula, Fortovia, freedom, freeze, furlough, genetic, Greenwich, headline, IBOR, immunocompromised, inseverable, intractable, IRPD, job, Kaplan, layout, magnitude, Medincell, medulloblastoma, Meier, metastasize, modest, monthly, nationwide, Novation, nurse, overturn, pen, permissible, pocket, pseudonymized, quarantine, realigned, realistic, Reauthorization, reciprocal, reconsideration, remanded, singular, soft, spinal, standalone, stead, strongly, Supreme, syringe, template, tender, tentative, tie, tied, tier, Tunable, unaudited, unconstitutional, uneven, unnecessary, Unrecognised, unsatisfactory, upheld, usage, Variation, ventricle, voluntarily, white, worker, worsen
Removed: aa, activist, addressing, administer, adult, afford, altering, amend, AMP, analogue, anniversary, antigen, Article, attacking, austerity, automatic, brand, Brisbane, brokerage, buyer, capped, carcinoid, cardiovascular, Center, certificated, chiefly, clinic, commensurate, concentration, conjugated, consortium, costing, dampen, deeper, depot, derive, Deutsche, die, efficiency, emergence, enhancing, enlargement, equitable, Excellence, excessive, excise, excretability, extraordinary, fatal, feedback, fit, focal, fulfil, gauge, GBP, golden, Griffith, Hack, hormone, immunogenic, inclusive, insolubility, Inspector, Institut, insulin, insured, invoiced, irrevocably, ISO, Israel, jurisdictional, la, lapsing, LAR, Leiden, Lisbon, lymph, Marseille, Medicale, membership, microencapsulation, mouth, multivalency, Mylan, negotiated, newly, NHS, NI, NICE, nm, nonbinding, Obama, obligatory, Opsisporin, outpatient, outright, Oxfordshire, pain, palliative, parachute, pituitary, prorated, QLD, Queen, Recherche, reclassification, regime, registrar, Releasability, removal, reproducible, repurpose, restarted, restate, returning, rotation, SA, Sandostatin, Sante, Senate, sequestration, sharing, SMT, solution, somatostatin, Sphera, staffing, step, stipulate, suffering, survive, Sweden, syndrome, tablet, telex, thereon, transbuccal, transport, TRNX, unanimously, uncertificated, underway, usable, validly, Woodford

Proxies

No filings

Patents

APP
Utility
Cyclodextrin-Panobinostat Adduct
25 Nov 20
The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct.
GRANT
Utility
Cyclodextrin-panobinostat adduct
27 Jul 20
The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct.
GRANT
Utility
Nanoparticles and their use in cancer therapy
22 Jun 20
The present invention provides a nanoparticle comprising a core comprising a metal; and a corona comprising a plurality of ligands covalently linked to the core, the plurality of ligands including at least a first species of ligand comprising an ethylene glycol portion and an amine group and at least a second species of ligand comprising a carbohydrate group, for use in a method of treating a cancer, particularly skin cancer, in a mammalian subject.